• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Taiwan, China starts study on efficacy of mixing AZ, Moderna COVID vaccines

firstwordpharmaAugust 02, 2021

Tag: AZ , Moderna , COVID vaccines

A hospital in Taiwan, China has begun a clinical study investigating a mix and match approach with COVID-19 vaccines from AstraZeneca and Moderna, Taiwan, China News reported.

Taiwan, China starts study on efficacy of mixing AZ, Moderna COVID vaccines

The trial, which is being carried out by the National Taiwan, China University Hospital (NTUH), includes four groups of 100 subjects, with the first two receiving doses of AstraZeneca and Moderna's vaccines four or eight weeks apart.

Meanwhile, the third group will receive two doses of AstraZeneca's vaccine eight weeks apart, with the final group given two doses of Moderna's vaccine, also eight weeks apart


Previous:Pfizer and Moderna raise prices for its COVID-19 vaccines in EU

Next:UK scientists believe it is 'almost certain' a coronavirus variant will emerge that beats current vaccines

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Taiwan, China starts study on efficacy of mixing AZ, Moderna COVID vaccines | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

1-(1-Benzothiophen-4-yl)piperazine hydrochloride

1-(1-Benzothiophen-4-yl)piperazine hydrochloride
Xylazine hydrochloride

Xylazine hydrochloride
Esomeprazole sodium impurity 2

Esomeprazole sodium impurity 2
5,6-DIPHENYLPYRAZIN-2-OL

5,6-DIPHENYLPYRAZIN-2-OL
1-Methyl-1H-pyrazole-5-boronic acid

1-Methyl-1H-pyrazole-5-boronic acid
Levofloxacin Q Acid(100986-89-8) 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylicacid, 9,10-difluoro

Levofloxacin Q Acid(100986-89-8) 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylicacid, 9,10-difluoro
6-chloro-3-hydroxypyrazine-2-carboxamide

6-chloro-3-hydroxypyrazine-2-carboxamide
2-Benzoyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one

2-Benzoyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one
2-((5-bromo-4-(4- ethylnaphthalen-1-yl) -4H- 1,2,4-triazol-3-yl)th io)acetic acid

2-((5-bromo-4-(4- ethylnaphthalen-1-yl) -4H- 1,2,4-triazol-3-yl)th io)acetic acid
2-(3-chloro-5-(phenanthren-9-yl)phenyl)-4,6-diphenyl-1,3,5-triazine

2-(3-chloro-5-(phenanthren-9-yl)phenyl)-4,6-diphenyl-1,3,5-triazine

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service